-

Vetter Once Again Wins Axia Best Managed Companies Award

Honor confirms continuity and the pharmaceutical service provider's approach to sustainability

  • Internationally renowned seal of quality for exemplary corporate management
  • Positive assessment of strategy, innovation, culture and finance
  • Comprehensive, multi-stage application procedure

RAVENSBURG, Germany--(BUSINESS WIRE)--For the second time in a row, Vetter, a global leading contract development and manufacturing organization (CDMO), has won the Axia Best Managed Companies Award. The pharmaceutical service provider was again honored for its clear vision, innovative approaches, sustainable management culture and sound financial management. Every year, Deloitte Private, the prominent German business journal WirtschaftsWoche, Credit Suisse and the Bundesverband der Deutschen Industrie (the Federation of German Industries) select which medium-sized companies are best managed and thus receive the renowned award. In keeping with the current pandemic situation, the ceremony was held on a small scale at the headquarters of the family-owned company in Ravensburg.

Once again, Vetter has proven that stability and progress are possible – even during these challenging times. The pharmaceutical service provider presented convincing evidence in the evaluated categories – starting with the competent handling of the current challenges posed by the COVID-19 pandemic, to the successful acquisition of a new production site in Vorarlberg, Austria, as well as its new company strategy, Vetter Next 2029, which is currently in progress.

The Axia Best Managed Companies Program is established in over 30 countries. By winning the award, recipients become part of an exclusive national and global network of successful companies. The three-stage application process is very demanding. The companies' performance in the key categories strategy, productivity and innovation, culture and commitment, as well as finance and governance are analyzed. As a last step, an independent jury consisting of high-ranking representatives from business, science and the media must also weigh in on the best choice for a winner. The award-winning companies were able to demonstrate an outstanding performance pursuant to the criteria and exemplary best practices.

“From the development of visionary strategies and innovative processes to effective corporate governance structures and a healthy corporate culture – as an award winner, Vetter is characterized by entrepreneurial excellence. Once again, they have set new standards in several key areas of corporate governance,” emphasized Lutz Meyer, partner and head of Deloitte Private.

“This award is dedicated to our 5,500 staff members worldwide,” said Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family. “The special spirit of our family-owned company is particularly evident in these challenging times.” For the company and its staff members, winning the award once again is considered both a trusted confirmation and a strong motivation. Managing Directors Thomas Otto and Peter Soelkner shared, “We are honored to receive the Axia Best Managed Companies Award for the second time in a row. Vetter is focused on acting in a proactive and sustainable manner – now and into the future.”

Find the Vetter press kit and more background information here.

About Vetter

Headquartered in Ravensburg, Germany, Vetter is a family-owned, global leading contract development and manufacturing organization (CDMO) with production facilities in Germany, Austria and the United States. Currently employing more than 5,500 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.

Contacts

Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Phone: +49 (0)751-3700-3729
E-mail: PRnews@vetter-pharma.com

Vetter


Release Versions

Contacts

Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Phone: +49 (0)751-3700-3729
E-mail: PRnews@vetter-pharma.com

More News From Vetter

Pharmaceutical Service Provider Vetter Pharma to Build New Manufacturing Site in Germany

RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter, one of the world's leading pharmaceutical service providers for the production of injectable drugs, has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany. This strategic investment marks a significant milestone in the company’s long-term global growth strategy. Construction is scheduled to begin in the second quarter of 2026. Initially, approximately €480 million have been allocated for t...

Vetter Achieves Top Sustainability Rating and Expands Climate Goal Commitments

RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has strengthened its sustainability strategy with distinguished recognitions: the internationally renowned EcoVadis Platinum rating as well as the official validation of its emission reduction targets by the Science Based Targets initiative (SBTi). Both achievements highlight the company’s commitment to climate protection and responsible business practices. For the fourth...

Vetter Reaches Key Launch Milestones for the V-OVS® next Tamper-Evident Syringe Closure System

RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has completed several important steps in the ongoing development and upcoming launch of V-OVS® next. Developed from extensive market feedback, this new closure system will feature several important updates: intuitive handling, innovative functionality and a premium design, that fits a wide range of syringe formats. Together these advances will further enhance the protec...
Back to Newsroom